QL1706 injection

DRUG3 trials

Sponsors

Qilu Pharmaceutical Co., Ltd., Tianjin Medical University Cancer Institute and Hospital

Conditions

Advanced Solid TumorsBreast CancerCarcinoma, Non-Small-Cell Lung

Phase 1

A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors

Qilu Pharmaceutical Co., Ltd.Advanced Solid Tumors

Start: 2021-01-11End: 2023-12-31Updated: 2023-04-07

Phase 2

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Not yet recruitingNCT07246317

Tianjin Medical University Cancer Institute and HospitalBreast Cancer

Start: 2025-12-15End: 2032-12-31Target: 188Updated: 2025-11-28

Phase 3

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

RecruitingNCT05487391

Qilu Pharmaceutical Co., Ltd.Carcinoma, Non-Small-Cell Lung

Start: 2022-12-08End: 2029-05-22Target: 632Updated: 2024-10-15

Related Papers

Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.

2025-10-03

A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.

Journal of Clinical Oncology2023-06-013 citations

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Journal of Hematology & Oncology2023-05-0839 citations

Abstract CT520: The safety summary of the phase 1a/b trial of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced malignant tumors

Cancer Research2022-06-151 citations

Efficacy and safety of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced cervical cancer: Cohort data from a phase 1b trial.

Journal of Clinical Oncology2022-06-013 citations

Efficacy and safety of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced nasopharyngeal carcinoma (NPC): Pooled cohort data from phase 1a/1b trials.

Journal of Clinical Oncology2022-06-011 citations